Different regulation of MHC class I antigen processing components in human tumors.
about
Exercise in Regulation of Inflammation-Immune Axis Function in Cancer Initiation and ProgressionTargeting Epigenetic Processes in Photodynamic Therapy-Induced Anticancer ImmunityHarnessing immunosurveillance: current developments and future directions in cancer immunotherapyUnderstanding the Impact of ErbB Activating Events and Signal Transduction on Antigen Processing and Presentation: MHC Expression as a Model.Epigenetic mechanisms regulate MHC and antigen processing molecules in human embryonic and induced pluripotent stem cellsHuman cord blood progenitors with high aldehyde dehydrogenase activity improve vascular density in a model of acute myocardial infarction.Osteosarcoma is characterised by reduced expression of markers of osteoclastogenesis and antigen presentation compared with normal boneCAR-modified T-cell therapy for cancer: an updated review.Inflammation-related genetic variations and survival in patients with advanced non-small cell lung cancer receiving first-line chemotherapyChimeric antigen receptors for T cell immunotherapy: current understanding and future directionsThe cancer exome generated by alternative mRNA splicing dilutes predicted HLA class I epitope density.Adoptive Cell Therapy of Melanoma with Cytokine-induced Killer CellsUpregulation of HLA Expression in Primary Uveal Melanoma by Infiltrating LeukocytesCan pharmacological receptor tyrosine kinase inhibitors sensitize poor outcome breast tumors to immune-based therapies?Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells.CAR-T cell therapy in gastrointestinal tumors and hepatic carcinoma: From bench to bedside.Chimeric antigen receptor-engineered T cells for immunotherapy of cancer.Ten years of progress in vaccination against cancer: the need to counteract cancer evasion by dual targeting in future therapies.Use of allogeneic NK cells for cancer immunotherapy.Targeting epigenetic mechanisms for clinical translation: enhancing the efficacy of tumor immunotherapies.The link between MHC class I abnormalities of tumors, oncogenes, tumor suppressor genes, and transcription factors.Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma.Deficiency of activated STAT1 in head and neck cancer cells mediates TAP1-dependent escape from cytotoxic T lymphocytes.Exposure to Melan-A/MART-126-35 tumor epitope specific CD8(+)T cells reveals immune escape by affecting the ubiquitin-proteasome system (UPS)Upregulation of HLA Class I Expression on Tumor Cells by the Anti-EGFR Antibody Nimotuzumab.Cancer Immunotherapy Using CAR-T Cells: From the Research Bench to the Assembly Line.The prognostic impact of human leukocyte antigen (HLA) class I antigen abnormalities in salivary gland cancer. A clinicopathological study of 288 cases.TAP1 down-regulation elicits immune escape and poor prognosis in colorectal cancer.Aggressive Behavior in Silent Subtype III Pituitary Adenomas May Depend on Suppression of Local Immune Response: A Whole Transcriptome Analysis.Natural Killer Cell-Based Immunotherapy in Gynecologic Malignancy: A Review.
P2860
Q26775189-0D097787-0FFC-47E9-A988-772938D53ADDQ26797280-021332E4-ECF1-473F-B051-542C26ABC04CQ27021570-AC321BF8-ACA1-47A4-8080-AC2237A1FAA6Q27691330-15016ABB-4CE4-48D6-9128-073BE1132D80Q33564357-EA9B4939-C6B6-4F3C-9B7E-BEB6963D6A9CQ33758841-3DD2C34B-12D5-40D6-8900-3197766F9BF2Q34000267-DA8D5421-69F6-4CCF-B57C-9FD8932731FBQ34044213-13433CDC-7B54-49CA-8A97-E03E7E64E45FQ34076429-D6B9DAB1-440A-403A-A3C6-08D5E37D0B5FQ34248531-F3E3E5F8-2B5B-4324-8AF8-6F1522448478Q34437754-1DC9C366-D2FF-4923-A864-57BE5B8CF883Q35543911-147B20BF-AAF6-4DC8-9F0B-7265C02AEB3DQ36169054-67C907DD-7E69-4B64-8791-6162D3E470DAQ36605526-FBFE0425-80FA-47A4-A98F-3F67767DE822Q36946516-5818830B-28C1-46D4-970D-361AD1189112Q37559401-253EA631-DD56-454B-BAF8-D4E5EEC617E8Q37751873-6C1552A4-3AB2-400C-B7E4-9B5455BE8117Q37863518-13D3CD3C-97E7-4C1C-805A-92F4A026045EQ37957140-7862434B-395C-492A-9A8C-A648447EDBD8Q38159805-C141F20D-A898-4B63-8EA3-CC4665783CCEQ38183420-897EDE47-4B03-4E63-976C-E85DEAB2D0E4Q39190801-244AC284-6859-4880-9A91-230406AD8C64Q39612090-632083F8-9300-45AD-8C31-168B090FEA7CQ39796576-841DECED-7CB3-49E5-89DC-298D80657F2AQ43119856-FB6FDFEB-28D7-47A4-AAA6-06FD20506155Q45872592-51A34063-AAEA-4025-A8A4-0B6CA6DF5457Q46685091-59C97285-D7FD-4788-9063-E1A3A67F0657Q47393414-1FF19145-64A9-4FB6-8A16-3CF0B71CE9A5Q47784194-5D4729D1-604E-44C9-B2D0-CF10A75E0BD5Q49724715-B0635E58-3F31-41AB-84DB-61F145BB3B35
P2860
Different regulation of MHC class I antigen processing components in human tumors.
description
2008 nî lūn-bûn
@nan
2008 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Different regulation of MHC class I antigen processing components in human tumors.
@ast
Different regulation of MHC class I antigen processing components in human tumors.
@en
type
label
Different regulation of MHC class I antigen processing components in human tumors.
@ast
Different regulation of MHC class I antigen processing components in human tumors.
@en
prefLabel
Different regulation of MHC class I antigen processing components in human tumors.
@ast
Different regulation of MHC class I antigen processing components in human tumors.
@en
P2860
P1476
Different regulation of MHC class I antigen processing components in human tumors.
@en
P2093
Barbara Seliger
P2860
P304
P356
10.1080/15476910802482870
P577
2008-10-01T00:00:00Z